<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04857957</url>
  </required_header>
  <id_info>
    <org_study_id>CNTX-6016o-HV/PDN-102</org_study_id>
    <nct_id>NCT04857957</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability &amp; Pharmacokinetics Study of CNTX-6016 in Healthy Subjects and Subjects With PDN</brief_title>
  <official_title>A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CNTX-6016 in Healthy Subjects and a Single Cohort of Subjects With Painful Diabetic Neuropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centrexion Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centrexion Therapeutics</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 1b/2a study to evaluate the safety, tolerability and pharmacokinetics of multiple&#xD;
      ascending doses of CNTX-6016 in healthy subjects and a single cohort to evaluate painful&#xD;
      diabetic neuropathy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 14, 2021</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events (TEAEs) (safety and tolerability) with CNTX-6016</measure>
    <time_frame>Up to 45 days</time_frame>
    <description>Number of participants with TEAEs, which includes laboratory test variables</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CNTX-6016 Pharmacokinetics - Cmax</measure>
    <time_frame>Up to Day 6</time_frame>
    <description>Systemic exposure to CNTX-6016 measured by Cmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CNTX-6016 Pharmacokinetics - AUC0-t</measure>
    <time_frame>Up to Day 6</time_frame>
    <description>Systemic exposure to CNTX-6016 measured by AUC0-t</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CNTX-6016 Pharmacokinetics - t1/2</measure>
    <time_frame>Up to Day 6</time_frame>
    <description>Systemic exposure to CNTX-6016 measured by t1/2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CNTX-6016 Pharmacokinetics - tmax</measure>
    <time_frame>Up to Day 6</time_frame>
    <description>Systemic exposure to CNTX-6016 measured by tmax</description>
  </primary_outcome>
  <other_outcome>
    <measure>CNTX-6016 Effect of Age and Sex in all Cohorts</measure>
    <time_frame>Up to Day 14</time_frame>
    <description>Systemic exposure to CNTX-6016 By Cmax pooled from all cohorts over full dose range.</description>
  </other_outcome>
  <other_outcome>
    <measure>CNTX-6016 Effect of Age and Sex in all Cohorts</measure>
    <time_frame>Up to Day 14</time_frame>
    <description>Systemic exposure to CNTX-6016 By AUC pooled from all cohorts over full dose range.</description>
  </other_outcome>
  <other_outcome>
    <measure>CNTX-6016 Efficacy - PDN Cohort</measure>
    <time_frame>Up to Day 14</time_frame>
    <description>Efficacy measured by Numeric Rating Scale. The Numeric Rating Scale is an 11-point pain scale with a range of 0 to 10 where 0 = &quot;no pain&quot; and 10 = &quot;worst possible pain&quot;</description>
  </other_outcome>
  <other_outcome>
    <measure>CNTX-6016 Efficacy - PDN Cohort</measure>
    <time_frame>Up to Day 14</time_frame>
    <description>Efficacy measured by PainDETECT Questionnaire</description>
  </other_outcome>
  <other_outcome>
    <measure>CNTX-6016 Efficacy - PDN Cohort</measure>
    <time_frame>Up to Day 14</time_frame>
    <description>Efficacy measured by Patient Global Impression of Change</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Painful Diabetic Neuropathy</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 mg oral dose TID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>600 mg oral dose TID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>800 mg oral dose TID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PDN cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose based on safety in healthy Cohorts 1-3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral dose CNTX-6016 or oral dose Placebo</intervention_name>
    <description>CNTX-6016 or Placebo</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>PDN cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Is in good general health as determined by Investigator's review.&#xD;
&#xD;
          -  Has a body mass index (BMI) between 18 and 35 kg/m2.&#xD;
&#xD;
          -  Non- or ex-smoker (&gt; 1 year) and has not used any nicotine containing products within&#xD;
             12 months prior to screening.&#xD;
&#xD;
          -  For females, is not currently pregnant and is either of non-childbearing potential or&#xD;
             willing to use an adequate method of birth control.&#xD;
&#xD;
          -  For males, must agree to use barrier contraception and not to donate sperm&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Is pregnant, lactating, or planning a pregnancy during the study.&#xD;
&#xD;
          -  Tests positive for COVID-19 after screening is complete and subject is confirmed to&#xD;
             enroll&#xD;
&#xD;
          -  History of or active cardiac disease, including congestive heart failure, angina, or&#xD;
             any arrhythmia.&#xD;
&#xD;
          -  Has any history or currently active type of cancer except excised or cured basal cell&#xD;
             carcinoma.&#xD;
&#xD;
          -  Has an immunological disorder such as, but not limited to, human immunodeficiency&#xD;
             virus (HIV), acquired, or congenital immune deficiency syndrome; autoimmune diseases,&#xD;
             such as, but not limited to, rheumatoid arthritis, systemic lupus erythematosus,&#xD;
             seronegative spondyloarthropathies or vasculitis, or any infection.&#xD;
&#xD;
          -  Positive urine screen for alcohol, cotinine, THC and/or drugs of abuse&#xD;
&#xD;
          -  Has positive screening test for hepatitis B virus (HBV) or hepatitis C virus (HCV).&#xD;
&#xD;
        Key Inclusion Criteria- PDN Cohort&#xD;
&#xD;
          -  A diagnosis/history of Type 2 diabetes mellitus&#xD;
&#xD;
          -  The pain is present in both feet/legs with symmetrical onset&#xD;
&#xD;
          -  The pain is characterized as burning, painful, cold or electrical shocks in nature&#xD;
&#xD;
          -  The pain is associated with tingling, numbness, itching or pins and needles type&#xD;
             sensations&#xD;
&#xD;
          -  The pain has been present and consistent for â‰¥ 6 months&#xD;
&#xD;
        Key Exclusion Criteria- PDN Cohort&#xD;
&#xD;
          -  Diagnosis of Type 1 diabetes&#xD;
&#xD;
          -  Has serious or unstable cardiovascular, hepatic, renal, respiratory or hematological&#xD;
             illness&#xD;
&#xD;
          -  Has a history or currently active type of cancer except excised or cured basal cell&#xD;
             carcinoma.&#xD;
&#xD;
          -  Has a History of psychological conditions or neurological disorders&#xD;
&#xD;
          -  Has a History of lower back pain with radiculopathy&#xD;
&#xD;
          -  Has received non-pharmacological treatment for pain within 14 days&#xD;
&#xD;
          -  Has a history of frequent and/or severe allergic reactions with multiple medications&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Tiseo, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Centrexion Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study manager</last_name>
    <phone>617-837-6911</phone>
    <email>info@centrexion.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>AltaSciences</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Kankam, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 19, 2021</study_first_submitted>
  <study_first_submitted_qc>April 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 23, 2021</study_first_posted>
  <last_update_submitted>April 22, 2021</last_update_submitted>
  <last_update_submitted_qc>April 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Painful Diabetic Neuropathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Neuropathies</mesh_term>
    <mesh_term>Pain</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

